Is the trade name of Infliximab Rex?

Infliximab (Infliximab) is a biological agent composed of a chimeric monoclonal antibody that mainly targets tumor necrosis factor α (TNF-α). This cytokine plays an important role in a variety of chronic inflammatory diseases. It is particularly effective in immune system abnormalities such as rheumatoid arthritis, Crohn's disease (CD), ulcerative colitis, ankylosing spondylitis and psoriatic arthritis. The earliest and most well-known trade name of infliximab is Remicade, which is often called "Leike" in Chinese. Remicade is an original research product jointly developed by Johnson & Johnson (Janssen) and Merck & Co. (MSD). It was first approved for marketing in the United States in 1998 and has gradually expanded to many countries and regions around the world.

In the Chinese market,"Like" is the trade name of Infliximab. It was first introduced as an imported drug and is still widely used, especially in hospitals and other places. Due to its rapid onset of action, stable efficacy, and wide range of indications, infliximab is regarded as one of the "gold standards" in the long-term management of many inflammatory diseases. Despite its higher price, its clinical position remains solid in the control of moderate to severe active disease.

It is worth mentioning that as patents expire, a variety of biosimilar drugs have begun to be launched globally. These biosimilar drugs are highly imitative of the original products in terms of pharmacological structure. Their efficacy and safety have been certified through strict comparative tests. They have been approved by authoritative agencies such as FDA and EMA, and have gradually entered the medical insurance systems of many countries.

However, in the Chinese mainland market, it is still mainly represented by "Leike", which is sold as an imported original research version. Although some biosimilar drugs have been approved, doctors and patients still have high trust in infliximab. Therefore, from the perspective of drug registration and circulation, Reike is the representative trade name of the original research of infliximab, representing the imported version, and has complete original data support and global clinical practice basis. It is currently one of the earliest and most commonly used versions for Chinese patients.

Reference materials:https://www.drugs.com/infliximab.html